Trial Profile
A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs BMS 986148 (Primary) ; Nivolumab
- Indications Adenocarcinoma; Gastric cancer; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 11 Nov 2021 Status changed from active, no longer recruiting to discontinued.
- 06 Oct 2021 Results published in the Clinical Cancer Research
- 05 Apr 2021 This trial has been completed in Netherland (Global End Date: 07 May 2020), according to European Clinical Trials Database record.